Other
Spondyloarthropathy
12
Pipeline Programs↗
0
Active Trials↗
8
Companies Involved↗
Spondyloarthropathy is an emerging landscape with 12 programs across 8 companies. The most active players are Novartis, Gilead, Johnson & Johnson. 5 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 21
Analysis
Modality Breakdown
12programs
Small molecule758%
Monoclonal antibody433%
Protein / enzyme18%
Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
3
clinical trials
Unknown status1 · 33%
Withdrawn1 · 33%
Completed1 · 33%
Clinical Trials
Trial Activity
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy
Unknown status·IItalian Group for the study of Inflammatory Bowel Disease (IG-IBD)·N/A·NCT05431283·100 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)